Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Korean J Hepatol. 2011 Sep;17(3):220-5. doi: 10.3350/kjhep.2011.17.3.220.

Peginterferon alpha and ribavirin combination therapy in patients with hepatitis C virus-related liver cirrhosis.

Author information

  • 1Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Korea.

Abstract

BACKGROUND/AIMS:

Pegylated interferon (peginterferon) and ribavirin combination therapy is less effective and associated with a higher frequency of serious complications in chronic hepatitis C patients with cirrhosis than in noncirrhotic patients. This study evaluated the efficacy and tolerability of peginterferon and ribavirin treatment in patients with hepatitis C virus (HCV)-related cirrhosis.

METHODS:

Eighty-six patients with clinically diagnosed liver cirrhosis were treated with either peginterferon alpha-2a (n=51) or peginterferon alpha-2b (n=35) plus ribavirin. The sustained virologic response (SVR) and adverse effects were analyzed retrospectively.

RESULTS:

Of the 86 patients (55 males), 48 patients (55.8%) had HCV genotype 1 infection and 38 (44.2%) had genotype non-1 infection. The overall SVR rate was 34.9% (30/86), and the rates of SVR in the genotype 1 and non-1 patients were 20.8% (10/48) and 52.6% (20/38), respectively. The multivariate analysis revealed that having HCV genotype 1 (P=0.003) and high baseline viral load (<8.0×10(5) IU/mL, P=0.012) were the independent predictive factors for SVR failure. In 20.9% (18/86) of the patients, treatment was not completed due to adverse events (27.8%), loss to follow-up (50.0%), and other reasons (22.2%).

CONCLUSIONS:

Peginterferon and ribavirin combination therapy was relatively effective and feasible for clinically diagnosed HCV patients, especially in those with genotype non-1 infection and low baseline viral load.

PMID:
22102389
[PubMed - indexed for MEDLINE]
PMCID:
PMC3304650
Free PMC Article

Images from this publication.See all images (2)Free text

Figure 1
Figure 2
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for The Korean Association for the Study of the Liver Icon for PubMed Central
    Loading ...
    Write to the Help Desk